News | September 27, 2024
Alkem denies claims of Pan-D, Clavam 625 batches being substandard quality
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
New Phase II data show vast majority of patients experiencing no relapses or disability progression
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Subscribe To Our Newsletter & Stay Updated
